Orient Gene Biotech has obtained Coronavirus Test Device Approval (CTDA) from the UK

Rapid COVID-19 Antigen Self-Test developed by Orient Gene Biotech has obtained Coronavirus Test Device Approval (CTDA) from the UK for a period of 5 years. After obtaining certification, the Rapid COVID-19 Antigen Self-Test products are available for sale within the UK.


The Rapid COVID-19 Antigen Self-Test developed by Orient Gene Biotech uses nasal swab samples to detect whether there is infection with COVID-19. It is used for the detection of both symptomatic and asymptomatic individuals. The Rapid COVID-19 Antigen Self-Test has the following characteristics:


  • High sensitivity and specificity

  • Easy to use

  • Easy to interpret results in 15 minutes

  • Available for use at home

  • Early detection and treatment

  • Available in variable pack sizes



The certification of Rapid COVID-19 Antigen Self-Test signifies that the use of the 2019-nCoV antigen detection reagent developed by Orient Gene Biotech has been fully recognized, and it has been authorized to evolve from emergency-use to long-term certification, aiding in the UK’s containment efforts for the COVID-19 virus.

At present, with the reoccurrence of COVID-19, Orient Gene Biotech will continue to pool global scientific and technological strength to provide full support for the global fight against COVID-19.